Title

Core-Binding Factor Acute Myeloid Leukemia: Heterogeneity, Monitoring, And Therapy

Abstract

Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are addressing the molecular heterogeneity, minimal residual disease and targeted therapies to improve the outcome of CBF AML. In this article, we present a comprehensive review about CBF AML with emphasis on molecular heterogeneity and new therapeutic options.

Publication Date

12-1-2014

Publication Title

American Journal of Hematology

Volume

89

Issue

12

Number of Pages

1121-1131

Document Type

Review

Personal Identifier

scopus

DOI Link

https://doi.org/10.1002/ajh.23821

Socpus ID

84922393117 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/84922393117

This document is currently not available here.

Share

COinS